CL2023001258A1 - Compuesto degradante en un medicamento - Google Patents

Compuesto degradante en un medicamento

Info

Publication number
CL2023001258A1
CL2023001258A1 CL2023001258A CL2023001258A CL2023001258A1 CL 2023001258 A1 CL2023001258 A1 CL 2023001258A1 CL 2023001258 A CL2023001258 A CL 2023001258A CL 2023001258 A CL2023001258 A CL 2023001258A CL 2023001258 A1 CL2023001258 A1 CL 2023001258A1
Authority
CL
Chile
Prior art keywords
medicine
brimonidine
carbachol
impurities
less
Prior art date
Application number
CL2023001258A
Other languages
English (en)
Inventor
Mead SCHIFFMAN Rhett
Alan Firestone Bruce
Original Assignee
Visus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visus Therapeutics Inc filed Critical Visus Therapeutics Inc
Publication of CL2023001258A1 publication Critical patent/CL2023001258A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se dirige a formulaciones oftalmológicas que comprenden carbacol, brimonidina, y menos del 5 % de una o más impurezas, procesos para preparar formulaciones oftalmológicas que comprenden carbacol, brimonidina, y menos del 5 % de una o más impurezas, y métodos para tratar la presbicia y otras afecciones oftalmológicas mediante la administración de formulaciones oftalmológicas que comprenden carbacol, brimonidina y menos de 5 % de una o más impurezas.
CL2023001258A 2020-11-02 2023-05-02 Compuesto degradante en un medicamento CL2023001258A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108720P 2020-11-02 2020-11-02
US202163162367P 2021-03-17 2021-03-17
US202163257024P 2021-10-18 2021-10-18

Publications (1)

Publication Number Publication Date
CL2023001258A1 true CL2023001258A1 (es) 2023-12-22

Family

ID=81383327

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001258A CL2023001258A1 (es) 2020-11-02 2023-05-02 Compuesto degradante en un medicamento

Country Status (12)

Country Link
US (2) US20230390284A1 (es)
EP (1) EP4236932A1 (es)
JP (1) JP2023548336A (es)
KR (1) KR20230104645A (es)
AU (1) AU2021369566A1 (es)
CA (1) CA3195784A1 (es)
CL (1) CL2023001258A1 (es)
CO (1) CO2023007133A2 (es)
CR (1) CR20230190A (es)
MX (1) MX2023005031A (es)
TW (1) TW202233170A (es)
WO (1) WO2022094462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117571883B (zh) * 2024-01-15 2024-03-19 四川智强医药科技开发有限公司 一种酒石酸溴莫尼定滴眼液的质量检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980818B2 (en) * 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
MX2012008516A (es) * 2010-01-21 2012-10-15 Allergan Inc Agonista alfa-2 adrenergico que tiene larga duracion de efecto de baja presion intraocular.
EP4385521A2 (en) * 2015-06-18 2024-06-19 Lenz Therapeutics, Inc. Storage stable compositions and methods for the treatment of refractive errors of the eye
MX2018011300A (es) * 2016-03-17 2019-02-18 Presbyopia Therapies Llc Composiciones y metodos para el tratamiento de la presbicia.
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof

Also Published As

Publication number Publication date
TW202233170A (zh) 2022-09-01
CA3195784A1 (en) 2022-05-05
MX2023005031A (es) 2023-06-29
KR20230104645A (ko) 2023-07-10
JP2023548336A (ja) 2023-11-16
AU2021369566A1 (en) 2023-06-22
EP4236932A1 (en) 2023-09-06
CR20230190A (es) 2023-09-06
WO2022094462A1 (en) 2022-05-05
US20230390284A1 (en) 2023-12-07
CO2023007133A2 (es) 2023-06-20
US20240100046A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
NI202100009A (es) Métodos para reducir la necesidad de revascu
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CO2020006009A2 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
CL2023001258A1 (es) Compuesto degradante en un medicamento
CR11724A (es) Agente para tratar enfermedades
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
ECSP22091485A (es) Imidazolpiridazinas como moduladores de il-17
MX2022013323A (es) Compuestos triciclicos como inhibidores de nlrp3.
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2023003459A (es) Nuevos compuestos.
CO2024001256A2 (es) Compuesto inductor de la degradación de plk1 novedoso
CL2023002914A1 (es) Dosificación y administración de l-asparaginasa recombinante
CO2019000513A2 (es) Formas cristalinas de un compuesto de tetraciclina sustituido con 9-aminometilo y un método de preparación de las mismas
BR112017025189A2 (pt) composição e usos da mesma
UY35059A (es) Método y composición para el tratamiento de ectoparásitos
CO2021012893A2 (es) Polímero superabsorbente y método para aumentar el contenido de azúcar en plantas
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
CL2021003301A1 (es) Éster isopropílico de ácido [((1r,2s,5r)-2-isopropil-5-metilciclohexanocarbonil)-amino]-acético para el tratamiento de la tos crónica.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
AR127641A1 (es) Método y composición para inhibir la formación de melanoidina en un proceso de propagación de la levadura
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres